GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

CanaQuest Medical CANQF · USD

N/A · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

About CanaQuest Medical

Its shares trade under the ticker CANQF. It has been listed since 27 October 2014. In the fiscal year to 31 March 2024, it reported revenue of C$45,945 and a net loss of C$1.9m. At that date it held total assets of C$291,613 and shareholders' equity of −C$1.5m.

CanaQuest Medical Corp. is a pharmaceutical company, which is focused on the medical cannabis products, utilizing cannabinoid molecules, and other botanical compounds. The company is headquartered in Mississauga, Ontario. The company went IPO on 2014-10-27. The firm is focused on the drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors. The Company’s drug candidates include CQ-001 and CQ-002. The firm is involved in the research and development of medical formulations and delivery systems to be used in human trials in order to apply for a Drug Identification Number (DIN) from the United States Food and Drug Administration (US-FDA). The firm is focused on treating neurological conditions, such as epilepsy, anxiety, depression, and post-traumatic stress disorder (PTSD), including addiction. The Company’s wholly owned subsidiary is ADC BioMedical Corp.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
27 Oct 2014
Website
ir.canaquest.com ↗

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • CanaQuest Medical Corp focuses on medical cannabis products using cannabinoid molecules and botanical compounds.
  • CanaQuest's drug candidates CQ-001 and CQ-002 target neurological conditions like epilepsy and PTSD.
  • ADC BioMedical Corp is a wholly owned subsidiary advancing medical formulations for human trials.

Weaknesses

  • CanaQuest's IPO date was 27 October 2014, which may indicate limited market experience.
  • The company relies on US-FDA approval for Drug Identification Numbers (DIN) for market entry.
  • CanaQuest's focus on neurological conditions limits its market scope to specific health segments.

Opportunities

  • The US-FDA approval process offers a pathway for CanaQuest to enter the U.S. pharmaceutical market.
  • CanaQuest's research in endocannabinoid system therapeutics aligns with growing interest in cannabinoid-based treatments.
  • CanaQuest's subsidiary ADC BioMedical Corp can expand medical formulations for broader neurological applications.

Threats

  • The US-FDA approval process is lengthy and uncertain for CanaQuest's drug candidates.
  • CanaQuest's reliance on cannabinoid molecules faces regulatory challenges in the U.S. pharmaceutical market.
  • CanaQuest's focus on neurological conditions may face competition from established pharmaceutical companies.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.